Fresh analyses reshape Alzheon’s oral Alzheimer’s drug

New analyses suggest Alzheon’s therapy may protect the brain in genetically high-risk patients despite mixed Phase 3 results. Clinical trials are usually judged by a simple rule: they either meet their primary endpoint or they don’t. Clinical-stage biopharma Alzheon’s Phase 3 trial of its investigational oral Alzheimer’s therapy, valiltramiprosate (ALZ-801), fell into the latter category. […] The post Fresh analyses reshape Alzheon’s oral Alzheimer’s drug appeared first on Longevity.Technology .

This story was reported by Longevity.Technology. EUROPES curates Europe's most relevant coverage — read the full report at the original source.